top of page

Clinical Research

Along with normal clinical service,  wide range of clinical trials also provided in our center

We are actively recruiting patient to participate in the following clinical trials

Please send referral letter to medicaloncology@hku.hk  if interested

Recruiting clinical Trials 

Liver Cancer

Protocol Number

Protocol Title

Experimental agent

Principle Investigator

RELATIVITY-073 (CA224-073)

A Phase 2, Randomized, Open-label Study of Relatlimab in Combination with Nivolumab in Participants with Advanced Hepatocellular Carcinoma who are Naive to IO Therapy but Progressed on Tyrosine Kinase Inhibitors

Nivolumab VS Nivolumab + Relatlimab

Dr. Thomas Yau

Bile Duct Cancer

Protocol Number

Protocol Title

Experimental agent

Principle Investigator

Pancreatic Cancer

Protocol Number

Protocol Title

Experimental agent

Principle Investigator

PANOVOA-3

Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma

TTFields, 150kHz

with 

Gemcitabine and nab-paclitaxel

Dr. Thomas Yau

Breast Cancer

Protocol Number

Protocol Title

Experimental agent

Principle Investigator

CA209-7FL

A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer

Nivolumab

VS

Placebo

(Co-admin: standard Chemotherpay, endocrine therapy) 

Dr. Joanne Chiu

BO41843

A Phase III Randomized, Double-Blind, Placebo-controlled, Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Combined with Palbociclib Compared with Letrozole Combined with Palbociclib in Patients with Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Brease Cancer 

GDC-9545

VS

Letrozole

(Co-admin: Palbociclib)

Dr. Roland Leung

Lung Cancer

Protocol Number

Protocol Title

Experimental agent

Principle Investigator

KeyImPaCT / KEYNOTE-495 (MK-3475-495)

A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab - (MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)

pembrolizumab w/
MK-1308 (CTLA-4) or
MK-4280 (LAG3) or
lenvatinib (VEGF)

Dr. Joanne Chiu

MK-7684A-003

A Phase 3,  Multicenter, Randomized, Double-Blind Study of MK-7684 with Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab Monotherapy as First Line Treatment for Participants With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer

MK-7684A (vibostolimab + pembrolizumab)

Dr. Joanne Chiu

IMpassion030 (WO39391)

A Phase III, Multicenter, Randomised, Open-labelled STUDY Comparing Atezolizumab (Anti-PD-L1 Antibody) in combination with adjuvant Anthracycline /Taxane-based chemotherapy versus Chemotherapy Alone in patients with operable triple-negative Breast Cancer

Paclitaxel, AC/EC

+/-

Atezoliumab

Dr. Joanne Chiu

Other Solid Tumor

Protocol Number

Protocol Title

Experimental agent

Principle Investigator

CPDR001X2X01B

Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments

PDR001

Dr. Joanne Chiu

IMbrella B
(BO40729)

A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

Atezolizumab

Dr. Roland Leung

STARTRK-2

An Open-Label, Multicenter, Global Phase2 Basket Study of Entrectinib for the treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Entrectinib

Dr. Thomas Yau

TIDENT-1

(TPX-0005-01)

Phase 2 Study 

NTRK1/2/3-/ROS-1/ALK-rearranged solid tumors 

Repotrectinib

Dr. Thomas Yau

FLX475-02

Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination with Pembrolizumab in Advanced Cancer

FLX45

+/-

Pembrolizumab

Dr. Joanne Chiu

Phase 1 Study

Protocol Number

Protocol Title

Experimental agent

Principle Investigator

WP41377

A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases

RO7119929

(TLR7 Agonist)

Dr. Thomas Yau

CS1002-101 

A phase IA/IB, open-label, dose-escalation, and dose-expansion study of the anti-CTLA-4 monoclonal antibody CS1002 as monotherapy and in combination with anti-PD-1 monoclonal antibody CS1003 in subjects with advanced solid tumors

CS1002 (CTLA4)

+/-

CS1003 (PD1)

Dr. Thomas Yau

CS1001/Regorafenib-101

A phase Ib/II, multicenter open-label study of CS1001 in combination with regorafenib in patients with advanced or refractory solid tumors

CS1001 (PD-L1), Regorafenib

Dr. Thomas Yau

YQ23-19002

A phase Ib, open-label, dose-escalation study of YQ23 as a single agent and in combination with pembrolizumab administered to patients with advanced solid tumors

YQ23

+/-

 pembrolizumab

Dr. Thomas Yau

V941-001

Phase 1 Study 

KRAS + NSCLC / CRC / PDAC

mRNA-5671 / V941

+/-

pembrolizumab

Dr. Joanne Chiu

4003.1

A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of a Study Drug in Subjects With Advanced Solid Tumors

HBM4003

Dr. Thomas Yau

BA3021-001

A phase 1/2 dose escalation and dose expansion study of BA3021 alone and in combination with nivolumab in patients with advanced solid tumors

BA3021
+/-
nivolumab

Dr. Thomas Yau

Research: Research
Liver Cancer
Breast Cancer
Lung Cancer
Solid tumor

IMbrave050 (WO41535)

A Phase 3, multicenter, randomised, open-label study of Atezolizumab (Anti-PD-L1 Antibody) Plus Bevacizumab versus Active Surveillance As Adjuvant Therapy in Patients with Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation 

Atezolizumab+ Bevacizumab 

VS

Active Surveillance

Dr. Thomas Yau

KEYNOTE-937 (MK-3475-937)

A Phase 3 double-blinded, two-arm Study to evaluate the Safety and Efficacy of Pembrolizumab versus Placebo as Adjuvant Therapy in participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation 

Pembrolizumab

VS

Placebo

Dr. Thomas Yau

EMERALD-2 (D910DC00001)

A Phase 3, randomised, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination with Bevacizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation 

Durvalumab 

+/-

 Bevacizumab

Dr. Thomas Yau

CA209-9DW

A Randomized, Multi-Center, Phase 3 Study of Nivolumab in Combination with Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants with Advanced Hepatocellular Carcinoma 

Nivolumab, Ipilimumab 

VS 

Sorafenib or Lenvatinib

Dr. Thomas Yau

EMERALD-1
(D933GC00001)

A Phase 3 Randomized, Double Blind, Placebo-Controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patient with Locoregional Hepatocellular Carcinoma

Durvalumab with TACE

VS

Durvalumab, Bevacizumab with TACE

Dr. Thomas Yau

FOENIX-CCA3 (TAS-120-301)

A Phase 3, Open-Label, Randomized Study of Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients with Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements FOENIX-CCA3​

Pembrolizumab
VS
Placebo

Dr. Thomas Yau

GO42661

A Phase II, Randomized, Double-Blind Placebo-Controlled Study Of Atezolizumab With Or Without Bevacizumab In Combination With Cisplatin Plus Gemcitabine In Patients With Untreated, Advanced Biliary Tract Cancer

Atezolizumab+ Bevacizumab VS Atezolizumab + Placebo

Dr. Thomas Yau

OBI-822-011

The GLORIA Study: A Phase 3, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients with High-Risk, Early-Stage Globo H-Positive Triple Negative Breast Cancer

OBI-822, OBI-821

VS

Placebo

Dr. Joanne Chiu

Bile Duct Cancer
Pancreatic Cancer

WO41554

A Phase III, Randomized, Double-Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of GDC-0077 Plus Palbociclib And Fulvestrant Versus Placebo Plus Palbociclub and Fulvestrant in Patients with PIK3CA-Mutant, Hormone receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer 

GDC-0077

VS 

Placebo

(Co-admin: Palbociclib, Fulvestrant)

Dr. Roland Leung 

20190147

A Phase 1, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects of Chinese Descent With Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation

AMG 510

Dr. Joanne Chiu

Phase 1
bottom of page